Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

122.65EUR
11:35am EDT
Change (% chg)

€4.30 (+3.63%)
Prev Close
€118.35
Open
€119.90
Day's High
€123.70
Day's Low
€119.55
Volume
2,663,512
Avg. Vol
2,451,107
52-wk High
€146.45
52-wk Low
€96.83

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German holding company active in the field of health care, nutrition and high-tech materials. It has three subgroups: HealthCare, involved in the research, development and production of health products for people and animals, CropScience, engaged in the crop protection and non-agricultural pest control, and... (more)

Overall

Beta: 0.99
Market Cap(Mil.): €97,869.27
Shares Outstanding(Mil.): 826.95
Dividend: 2.25
Yield (%): 1.90

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 28.06 35.45 35.59
EPS (TTM): 4.22 -- --
ROI: 7.40 15.51 14.96
ROE: 16.71 16.08 15.84
Search Stocks

BRIEF-Bayer launches immunostimulant Zelnate for animal health after US clearance

* bayer launches immunostimulant zelnate for animal health following authorization in the us Further company coverage: (Frankfurt newsroom)

3:36am EDT

Bayer heart failure drug cuts deaths in mid-stage trial

- Bayer will move a heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular treatments after the experimental medicine showed a "striking" reduction in deaths in a mid-stage trial.

31 Aug 2015

UPDATE 1-Bayer heart failure drug cuts deaths in mid-stage trial

* May launch in 2020/21, analysts see potential $2 bln sales (Updates with comment from lead investigator)

31 Aug 2015

Bayer moves heart drug to final tests after mid-stage success

Aug 31 - Bayer will move a new heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular medicine, after the experimental medicine proved better than an older rival in a mid-stage trial.

31 Aug 2015

German stocks - Factors to watch on August 31

FRANKFURT, Aug 31 - The DAX top-30 index looked set to open 1.2 percent lower on Monday, according to premarket data from brokerage Lang & Schwarz at 0631 GMT.

31 Aug 2015

Bayer One-A-Day plaintiffs beat dismissal of heart, immunity claims

- A federal judge in California has ruled that plaintiffs accusing Bayer of falsely stating that One-A-Day supplements can boost heart health and immunity have provided enough proof to survive the company's second bid to dismiss those claims.

20 Aug 2015

BRIEF-Bayer says Covestro unit names CEO and CFO

* Says Covestro management board named: Patrick Thomas and Frank H. Lutz confirmed as ceo and cfo Further company coverage:

13 Aug 2015

Bayer's MaterialScience open to M&A: Handelsblatt

FRANKFURT - MaterialScience, Bayer's plastics division, which plans to list on the stock exchange soon, could consider acquisitions, especially in polyurethane-related business, its head told a German paper.

10 Aug 2015

Bayer's MaterialScience open to M&A -Handelsblatt

FRANKFURT, Aug 10 - MaterialScience, Bayer's plastics division, which plans to list on the stock exchange soon, could consider acquisitions, especially in polyurethane-related business, its head told a German paper.

10 Aug 2015

German stocks - Factors to watch on August 10

FRANKFURT/BERLIN, Aug 10 - The DAX top-30 index looked set to open 0.5 percent higher on Monday, according to premarket data from brokerage Lang & Schwarz at 0602 GMT.

10 Aug 2015

Earnings vs. Estimates

Search Stocks